On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 2, 2013, Pages 229-231

  Holster, I Lisanne ^a   Hunfeld, Nicole G M ^a   Kuipers, Ernst J ^a   Kruip, Marieke J H A ^a   Tjwa, Eric T T L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antidote management; Apixaban; Coagulopathy; Dabigatran; Gastrointestinal bleeding; New oral anticoagulant; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; PROTHROMBIN COMPLEX; PROTON PUMP INHIBITOR;

ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOSCOPIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HEMOPERFUSION; HEMOSTASIS; HUMAN; NONHUMAN; RISK FACTOR; THROMBIN TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; COAGULANTS; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS, ENDOSCOPIC; HUMANS; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84879151748     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011; 9 Suppl 1:12-19.
2. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding - A systematic review and meta-analysis. Gastroenterology 2013. [Epub ahead of print].
3. Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol 2012; 26:125-140.
4. Sung JJ. Chapter 3. Gastrointestinal bleeding: Antiplatelets and anticoagulants. In: Gastrointestinal bleeding. Sung JJ, Kuipers EJ, Barkun AN. (eds). 2 edn. Wiley-Blackwell, London 2012.
5. National Institute for Health and Clinical Excellence. http:// www.nice.org.uk/usingguidance/commissioningguides/ anticoagulationtherapyservice/popbench.jsp Accessed March 12, 2013.
6. Barkun AN, Bardou M, Kuipers EJ, et al; International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152:101-113.
7. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127:457-465.
8. Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L. Laboratory Assessment of Novel Oral Anticoagulants: Method Suitability and Variability Between Coagulation Laboratories. Clin Chem 2013; 59: 807-814.
9. Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012; 108:191-198.
10. Holster IL, Kuipers EJ, Tjwa ET. Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy. Endoscopy 2013; 45:63-66.
11. Shingina A, Barkun AN, Razzaghi A, Martel M, Bardou M, Gralnek I; RUGBE Investigators. Systematic review: the presenting international normalised ratio (INR) as a predictor of outcome in patients with upper nonvariceal gastrointestinal bleeding. Aliment Pharmacol Ther 2011; 33:1010-1018.
12. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152:1-9.
13. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573-1579.
14. Godier A, Miclot A, Le Bonniec B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116:94-102.
15. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012, 87 Suppl 1:S141-145.
16. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011; (3):CD001886.
17. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013. [Epub ahead of print].